Hercules, CA — March 13, 2012 — Bio-Rad Laboratories, Inc.’s QX100 Droplet Digital PCR system won a Laboratory Equipment Readers’ Choice Award in the Biotech category. The awards will be presented today at a special reception during the Pittcon Conference & Expo 2012 being held at the Orange County Convention Center in Orlando, FL.
“The QX100 Droplet Digital PCR system provides single copy PCR resolution to accelerate discoveries and new strategies for the research of inherited disorders, cancer, and infectious disease,” said Richard Kurtz, Bio-Rad Division Marketing Manager, Gene Expression Division. “It is a great honor to have our PCR technology recognized by the researchers and laboratory professionals that compose Laboratory Equipment’s readership.”
The 4th annual award celebrates “excellence in product design and performance for the tools and materials used by scientists and engineers in research laboratories.” Laboratory Equipment readers voted for products online.
By partitioning a nucleic acid sample into ~20,000 nanoliter-sized droplets, the QX100 system delivers the precision necessary to determine copy number variation and detect rare mutant events. For CNV, the large number of replicates made possible by sample partitioning provides the precision necessary to resolve high-order copy number states. For rare event detection, partitioning increases sensitivity by isolating the target signal from competing background. Droplet digital PCR also enables gene expression analysis with ±10% precision.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies, for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Bio-Rad Laboratories, Inc.
312-997-2436 x 109